Mira Pharma (MIRA)
0.72
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K MIRA PHARMACEUTICALS, For: Sep 17
September 17, 2026 8:31 AM - SEC Filing
MIRA Pharmaceuticals submits Ketamir-2 Phase 2a protocol for IRB review
September 17, 2026 8:30 AM - StreetInsider
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
September 17, 2026 8:30 AM - StreetInsider
Maxim Group Starts MIRA Pharmaceuticals Inc (MIRA) at Buy
September 17, 2026 7:46 AM - StreetInsider
Form 8-K MIRA PHARMACEUTICALS, For: Sep 11
September 16, 2026 4:31 PM - SEC Filing
Miravalles Gold Corp. Files NI 43-101 Technical Report for Fairfield Gold Project, Nayarit, Mexico
September 3, 2026 8:02 AM - StreetInsider
MIRA Pharmaceuticals reports positive toxicology data for MIRA-55 pain drug
September 1, 2026 8:03 AM - StreetInsider
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
September 1, 2026 8:00 AM - StreetInsider
Form 10-Q MIRA PHARMACEUTICALS, For: Jun 30
August 12, 2026 4:18 PM - SEC Filing
Form 8-K MIRA PHARMACEUTICALS, For: Aug 06
August 6, 2026 8:00 AM - SEC Filing
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
August 6, 2026 8:00 AM - Globe NewsWire
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
August 6, 2026 8:00 AM - StreetInsider
Form 8-K MIRA PHARMACEUTICALS, For: Jul 27
July 31, 2026 5:00 PM - SEC Filing
MIRA Pharmaceuticals completes toxicology studies for two drug candidates
July 30, 2026 8:02 AM - StreetInsider
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
July 30, 2026 8:00 AM - StreetInsider
Form DEF 14A MIRA PHARMACEUTICALS, For: Jul 28
July 28, 2026 5:00 PM - SEC Filing
Mira Pharmaceuticals reports oral formulation progress for MIRA-55
July 10, 2026 8:02 AM - StreetInsider
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain
July 10, 2026 8:01 AM - StreetInsider
Form 8-K MIRA PHARMACEUTICALS, For: Jul 10
July 10, 2026 8:00 AM - SEC Filing
Form 8-K MIRA PHARMACEUTICALS, For: Jul 06
July 6, 2026 9:00 AM - SEC Filing
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction
July 6, 2026 9:00 AM - StreetInsider
Mira Pharmaceuticals reports new preclinical data on Mira-55
June 25, 2026 8:15 AM - StreetInsider
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
June 25, 2026 8:15 AM - StreetInsider
Form 8-K MIRA PHARMACEUTICALS, For: Jun 25
June 25, 2026 8:01 AM - SEC Filing
Full Article List
